Dynavax Technologies (NASDAQ:DVAX) COO David Novack Sells 30,000 Shares

Dynavax Technologies Corporation (NASDAQ:DVAX) COO David Novack sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total value of $464,700.00. Following the completion of the transaction, the chief operating officer directly owned 111,451 shares of the company’s stock, valued at approximately $1,726,375.99. This represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Dynavax Technologies Stock Down 0.1%

DVAX stock opened at $15.37 on Tuesday. The stock’s fifty day simple moving average is $11.21 and its two-hundred day simple moving average is $10.62. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. Dynavax Technologies Corporation has a 1-year low of $9.20 and a 1-year high of $15.49. The stock has a market cap of $1.80 billion, a P/E ratio of -41.54 and a beta of 0.88.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. Analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Capital Fund Management S.A. purchased a new stake in Dynavax Technologies in the 2nd quarter worth approximately $1,669,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Dynavax Technologies in the first quarter worth $2,477,000. Hudson Bay Capital Management LP raised its position in shares of Dynavax Technologies by 46.4% in the second quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock worth $5,373,000 after buying an additional 171,700 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Dynavax Technologies by 222.3% during the second quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock valued at $4,321,000 after buying an additional 300,421 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in Dynavax Technologies by 50.4% during the third quarter. Exchange Traded Concepts LLC now owns 200,976 shares of the biopharmaceutical company’s stock valued at $1,996,000 after buying an additional 67,375 shares during the period. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DVAX. William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Wall Street Zen raised Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.